However, a new CAR-T cell therapy called obecabtagene autoleucel could change this situation. CAR-T therapy (Chimeric Antigen ...

T-cell therapy is a revolutionary immunotherapy approach in which T cells are genetically modified to express a receptor that ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim ...

PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Interius BioTherapeutics, a clinical-stage company engineering targeted, programmable vectors for the precision delivery of genetic medicines, today ...

Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...

Dual ON/OFF-switch chimeric antigen receptor controlled by two clinically approved drugs. Proceedings of the National Academy of Sciences , 2024; 121 (44) DOI: 10.1073/pnas.2405085121 Cite This Page : ...

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim safety and ...

Autolus Therapeutics has secured US Food and Drug Administration (FDA) approval for Aucatzyl (obecaktagene autoleucel), its ...

Most cancer treatments—from chemotherapies to engineered immune cells—have a host of side effects, in large part because they ...